Biogen & Samsung Bioepis launch in U.S. their biosimilar to Roche's eye drug Lucentis
seekingalpha.com
finance
2022-06-02 14:15:53

SvetaZi/iStock via Getty Images Biogen (NASDAQ:BIIB) and commercialization partner Samsung Bioepis on Thursday announced the launch in the U.S. of their Byooviz injection, a biosimilar to Roche's (OTCQX:RHHBY) (OTCQX:RHHBF) Lucentis, which is a treatment for various eye diseases and disorders. BIIB said the list price for Byooviz will be $1,130/single use vial to administer 0.5mg via intravitreal injection, which is 40% lower than the current list price of Lucentis. Byooviz will be commercially available through major distributors across the U.
